Immunoexpression of cell cycle biomarkers in neuroblastoma samples and its correlation with prognostic factors

Noronha, Lúcia de; Araújo, Deli Grace de Barros; Gozzo, Priscilla do Carmo; Harada, Luana E; Percicote, Ana Paula; Nagashima, Seigo; Gugelmin, Elisabeth Schneider; Watanabe, Flora; Machota Junior, Milton Marcio; Cunha, Isabela Werneck da.
J. bras. patol. med. lab ; 49(1): 57-63, Jan.-Feb. 2013. ilus, tab
Artículo en Inglés | LILACS | ID: lil-674349

Documentos relacionados

  1. BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.
  2. Expression level of quiescin sulfhydryl oxidase 1 (QSOX1) in neuroblastomas.
  3. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma.
  4. Combined analysis of PHOX2B at two time points and its value for further risk stratification in high-risk neuroblastoma.
  5. Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.
  6. Identification and validation of core genes in tumor-educated platelets for human gastrointestinal tumor diagnosis using network-based transcriptomic analysis.
  7. The ganglioside G<sub>D2</sub> as a circulating tumor biomarker for neuroblastoma.
  8. Reduced 2,4-dienoyl-CoA reductase 1 is served as an unfavorable biomarker and is related to immune infiltration in cervical cancer.
  9. Scoring system for diagnosis and pretreatment risk assessment of neuroblastoma using urinary biomarker combinations.
  10. Prognostic and predictive biomarkers in paediatric solid tumours.